25
Participants
Start Date
April 1, 2019
Primary Completion Date
June 1, 2022
Study Completion Date
May 31, 2024
SHR1210
The patients will receive at least two cycles of SHR-1210 (200 mg, invdrip d1) every two weeks and be accessed for operational suitability every two cycles.
Apatinib
The patients will received apatinib (250mg po qd) until 10 ± 2 days before surgery.
S1
The patients will received S1 (50 mg/m2, po, bid, d1-d10) every two weeks and be accessed for operational suitability every two cycles.
Oxaliplatin
The patients will receive at least two cycles of oxaliplatin (85 mg/m2 d1) every two weeks and be accessed for operational suitability every two cycles.
Qilu hospital of Shandong univertisy, Jinan
Qilu Hospital of Shandong University
OTHER